Latest news with #SteveFuller
Yahoo
10-07-2025
- Science
- Yahoo
Nishan Forum highlights cultural diversity, global dialogue
QUFU, China, July 10, 2025 /PRNewswire/ -- A news report from Nishan in Qufu, East China's Shandong province, the birthplace of Confucianism and hometown of Confucius, has turned into a center of cultural exchanges, as global scholars and experts are gathering to discuss various topics related to world civilizations and human progress. The 11th Nishan Forum on World Civilizations opened in Qufu on July 9, attracting over 400 experts and scholars from more than 70 countries around the world. With the tagline "Beauty in Diversity: Nurturing Understanding among Civilizations for Global Modernization", the forum aims to foster global dialogue and deepen mutual understanding among diverse cultures. From the co-development of diverse civilizations to innovation in the era of artificial intelligence (AI), six keynote speeches were delivered during the opening ceremony. When envisioning the future, one concept stands out: "harmony in diversity". This is the ideal that the great Chinese sage Confucius presented to the world. "The future is not as a battlefield of civilizations but as a garden of civilizations," said Chhem Kieth Rethy, senior minister of the Royal Government of Cambodia, in his keynote speech. He also emphasized the timeliness of the forum's theme. According to Rethy, civilization should not be seen as a "soft" topic, "but as a foundation for resilient and peaceful societies". Steve Fuller from the Department of Sociology at University of Warwick in the United Kingdom discussed how to protect human creativity in a world of globalized AI. No human being produces something entirely alone, according to Fuller. This might be ignored while doing research, but AI reminds us of this fact, he added. Jean Louis Robinson Richard, ambassador of Madagascar to China, praised the forum as a valuable platform for deepening intercultural dialogue. "Through events like the Nishan Forum, China has made great contributions to promoting world peace and fostering harmony among diverse cultures and civilizations," he said. The forum will run through July 10, with participants engaging in dialogues on topics such as the origins and future development of civilizations, the global significance of Confucian culture, and the impact of artificial intelligence on the future of human civilization. In addition, seven parallel forums are being held, focusing on a range of topics including overseas Chinese communities, Confucian dialogue, China-Egypt exchanges on ancient civilizations, world cultural heritage, and traditional Chinese medicine. View original content: SOURCE Sign in to access your portfolio
Business Wire
19-06-2025
- Health
- Business Wire
Cycle Pharmaceuticals' HARLIKU™ (nitisinone) Tablets Receive First FDA-Approval as Treatment for Alkaptonuria (AKU)
BOSTON & CAMBRIDGE, England--(BUSINESS WIRE)--Cycle Pharmaceuticals announced that the FDA has approved HARLIKU (nitisinone) Tablets for the reduction of urine homogentisic acid (HGA) in adult patients with AKU. 1 Launching in July 2025, HARLIKU will be the first and only FDA-approved treatment for AKU, 1 an ultra-rare genetic metabolic disorder in which patients have a buildup of HGA that leads to osteoarthritis, ochronosis, and complications in the kidneys, and heart. 2 Patients with AKU often develop pain, reduced joint mobility, and require large joint replacements; the symptoms impede their physical functionality, emotional well-being, and quality of life. 2, 3 The approval of HARLIKU is based on data from a randomized, no-treatment controlled study of 40 patients with AKU. As part of the intramural research program of the National Human Genome Research Institute at the National Institutes of Health (NIH), Dr. Wendy J. Introne, MD and her team showed that nitisinone helped patients improve pain, energy levels, and physical functioning after three years of treatment, assessed using the 36-Item Short-Form Survey. 4 Steve Fuller, Chief Strategy Officer of Cycle Pharmaceuticals commented, "We are deeply grateful for Cycle's collaboration with Dr. Wendy Introne, Dr. Bill Gahl, and the broader team at the NIH, whose pioneering work laid the foundation for this FDA approval. We look forward to making HARLIKU available to U.S. AKU patients as soon as possible and remain committed to supporting the AKU community to the fullest extent of our capabilities." 'The approval of HARLIKU is an important advance for the AKU community. Our scientific team has translated decades of research into launching nitisinone as a new treatment option, and we stand hopeful that it can ease the significant burden of AKU,' said Dr. Wendy J. Introne, MD, of NIH's National Human Genome Research Institute (NHGRI). Building on the company's previous success in rare diseases, HARLIKU will be Cycle Pharmaceuticals' eighth commercial product in the US. Indications HARLIKU™ is indicated for the reduction of urine homogentisic acid (HGA) in adult patients with alkaptonuria (AKU). Important Safety Information Do not prescribe HARLIKU to patients allergic to nitisinone or any other contained ingredients. Warnings and Precautions: Ocular Symptoms and Hyperkeratotic Plaques Due to Elevated Plasma Tyrosine Level: Ocular signs and symptoms including keratitis, corneal opacities, corneal irritation, corneal ulcers, conjunctivitis, eye pain, and photophobia, have been reported in patients. Perform slit-lamp examination prior to treatment and regularly thereafter. Reexamine patients if symptoms develop or tyrosine levels are > 500 micromole/L. Assess plasma tyrosine levels in patients with an abrupt change in neurological status. Perform a clinical laboratory assessment, including plasma tyrosine levels, in patients with an abrupt change in neurological status. Leukopenia and Severe Thrombocytopenia In clinical trials, patients with hereditary tyrosinemia type 1 (HT-1) treated with another oral formulation of nitisinone and dietary restriction, developed reversible leukopenia, thrombocytopenia, or both. No patients developed infections or bleeding as a result of the episodes of leukopenia and thrombocytopenia. Monitor platelet and white blood cell counts during HARLIKU therapy. Adverse Reactions: The most common adverse reactions (≥1%) reported in patients with AKU taking nitisinone in clinical trials are elevated tyrosine levels, thrombocytopenia and keratitis. Drug Interactions: Nitisinone is a moderate CYP2C9 inhibitor and a weak CYP2E1 inducer. Potential clinical impact of Harliku administration with CYP2C9 substrates. Reduce the dosage of the co-administered drugs metabolized by CYP2C9 by half. Additional dosage adjustments may be needed. Nitisinone is an inhibitor of OAT1/OAT3. Potential clinical impact of administration with OAT1/OAT3 substrates. Patients should be monitored for potential adverse reactions. Use in Specific Populations: Pregnancy: Limited available data with nitisinone use in pregnant women are not sufficient to determine a drug-associated risk of adverse developmental outcomes. The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. Lactation: The developmental and health benefits of breastfeeding should be considered against the mother's clinical need for HARLIKU, along with potential adverse effects on the breastfed infant from HARLIKU or from the underlying maternal condition. Pediatric Use: The safety and effectiveness of HARLIKU have not been established in pediatric patients with AKU. Geriatric Use: Insufficient data from clinical studies of HARLIKU to determine if patients ≥ 65 years of age respond differently. Elderly patients should be cautious reflecting any decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. For more detailed information, please refer to the full Prescribing Information at 1-855-831-5413, or the FDA at: 1-800-FDA-1088 or US-HKU-2500032 | May 2025 References HARLIKU (nitisinone) Tablets. Prescribing Information. Cycle Pharmaceuticals Ltd Introne WJ, Perry M, Chen M. 2003 (updated 2021). Alkaptonuria. Available at: [Accessed May 29, 2025] Rudebeck M, Scott C, Sireau N, Ranganath L. 2020. A patient survey on the impact of alkaptonuria symptoms as perceived by the patients and their experiences of receiving diagnosis and care. JIMD Rep. 53(1):71-79. doi:10.1002/jmd2.12101 Spears KR, Rossignol F, Perry MB, et al. 2024 Patient-reported outcomes and functional assessments of patients with Alkaptonuria in a 3-year Nitisinone treatment trial. Mol Genet Metab. 143(1-2),108562. doi:10.1016/ ©2025 Cycle Pharmaceuticals Limited. All rights reserved. HARLIKU™ and Cycle Vita™ are trademarks of Cycle Pharmaceuticals Limited in the United States. About Cycle Pharmaceuticals Cycle Pharmaceuticals was founded in 2012 with the sole aim of delivering drug treatments and product support to the underserved rare disease community. Cycle Pharma focuses on rare genetic conditions in metabolic, immunology, urology, and oncology. In neurology, we focus on multiple sclerosis. Cycle Pharma is headquartered in Cambridge, UK and has offices in Boston, Massachusetts. For more information, please visit and follow us on X, LinkedIn and Facebook.
Yahoo
15-06-2025
- General
- Yahoo
Carpenters for Christ: Volunteers build new Fairburn church for free
A group of carpenters from around the country gathered in Fairburn to build a church for a congregation they have never met. Channel 2's Lori Wilson went to the construction site to find out how the men's mission led them here. [DOWNLOAD: Free WSB-TV News app for alerts as news breaks] Every year, Steve Fuller and a crew of about 125 contractors choose a mission and go build. 'It's unbelievable to see how much work is accomplished here in basically a week,' Fuller said. The group calls themselves Carpenters for Christ. Every year, they pick a project and donate their time and talent. In about a week, they raise a church somewhere in the US. This year, they're building Living Word Church Ministries in Fairburn, pastored by William O'Neal. 'It was like wow. Just wow... you know, it was hard to believe," he told Wilson. TRENDING STORIES: Hundreds of metro Atlanta dads gather at the library to promote reading Metro Atlanta charity that gives cars to families in need helps one of its own Inspired by faith, DeKalb County church goes solar with 340 panels O'Neal has been actively pastoring in the Fairburn community for 16 years. The church outside of four walls says it has been giving back and meeting needs. It trusted God when it came time to build a church, it would be done debt free. 'We bought the land. We bought the plan. We got all of the site work done,' O'Neal said. That miracle: a phone call from contractor Christopher Gilliam. 'It makes you feel good to be able to help people and know that you're building the kingdom of Christ,' Gilliam said. He told O'Neal that not only did he want to do the project, but he had a team of 125 carpenters from around the country who would come with him and do the work for free. 'I was like, you're gonna give me this news while I'm driving,' O'Neal joked. That was about three weeks ago. The Sunday before the work started, the carpenters worshipped with the congregation they came to help, even if the work started off with a rainy week. 'It doesn't matter if he blows the building down... or he sends rains every day: We're going to continue to serve him and just try to help people,' Fuller said. 'We're building a building but God is building a church," O'Neal said. When the men leave this weekend, the church will be 85% done. The pastor hopes to have the first service in the new building in late August. [SIGN UP: WSB-TV Daily Headlines Newsletter]
